Philips leads €15.9m project to develop image-guided drug-delivery
30 January 2009
Royal Philips Electronics is leading a major new European project to
develop drug-delivery technologies that could change the way treatment
for cancer and cardiovascular disease is delivered.
By delivering drugs directly to disease sites via the patient’s
bloodstream that are then activated by focused ultrasound pulses, the
SonoDrugs project aims to maximize the therapeutic efficiency and
minimize the side effects of drug treatments for cancer and
cardiovascular disease. The hope is that this level of control will also
provide a means of tailoring the therapy to individual patients.
The SonoDrugs project is a partnership between 15 European
Union-based industrial partners, university medical centres, and
academic institutions. It will run for four years and has a budget of
€15.9 million, €10.9 million of which is funded under the EU’s 7th
The SonoDrugs project has a two-pronged approach: magnetic resonance
imaging (MRI) guidance and ultrasound guidance. The MRI-guided drug
delivery will focus on cancer treatments.
Members of the SonoDrugs consortium are:
- industrial partners Philips (The Netherlands, Germany and
Finland), Nanobiotix (France) and Lipoid (Germany);
- university medical centres: Erasmus Medical Center (The
Netherlands) and Universitäts Klinikum Münster (Germany); and
- academic institutions: University of Cyprus (Cyprus), University
of Gent (Belgium), University of Helsinki (Finland), University of
London (United Kingdom), University of Tours (France), University
Victor Segalen Bordeaux (France), University of Technology Eindhoven
(The Netherlands) and the University of Udine (Italy).
Bookmark this page